Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Comment by Time4TAon May 29, 2011 4:10pm
217 Views
Post# 18641699

RE: RE: CHINA

RE: RE: CHINA
https://www.nytimes.com/2011/01/13/world/asia/13shanghai.html
THE VANISHING MIND

The shift in attitudes is remarkable. A decade ago, many families were ashamed to admit that their elders had such a disease. And because of a lack of awareness about the disease, many dementia patients were confined to the psychiatric wards of hospitals, which placed steel bars over the windows.
But today, a growing number of families are desperate to place relatives in a nursing home. The problem, health experts say, is that there simply are not enough.
Health experts are predicting severe strains on the state and on working families here. And those strains could be compounded by the lack of awareness about Alzheimer’s disease and other forms of dementia, even among medical professionals in China.
“This is an impending health crisis for China, and it may even exceed what’s happening in the U.S. because of the one-child policy,” said Rhoda Au, an associate professor at theBoston University School of Medicine.
Worries about the growing ranks of the elderly are amplified by what is being dubbed the 4-2-1 problem. In part because of the one-child policy, soon a single person in China will be expected to help support two parents and four grandparents. And as the elderly live longer, they are more likely to develop dementia, which requires expensive care.
Bullboard Posts